It has recently emerged that this fusion product evicts SMARCB1/hSNF5/BAF47 from the SWI/SNF chromatin remodelling complex along with wild-type SS18 [128] and that the modified complex then targets the SOX2 locus, inducing expression thereof which leads to increased cell proliferation, contributing to oncogenesis, so chromatin-related changes may ultimately hold the key, to a great extent, to the development of synovial and indeed other sarcomas; however, further epigenetic modifications, including through miRNAs, may also play a role. This evidence concerns the gene SMARCB1 and sarcoma.